Supernus Pharmaceuticals Inc (SUPN)
EBITDA Growth
-177.80%
Quarterly · Period ending:
SUPN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-177.80%period ending
Latest reported-177.80%period ending
SUPN Quarterly EBITDA YoY % (-42.25% → -177.80%)
Year-over-year change
High-resolution chart · PNG
SUPN ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -177.8026% | |
| 13.5324% | |
| -41.0264% | |
| -150.9616% | |
| -2.3246% | |
| 7.7935% | |
| 99.5368% | |
| 104.892% | |
| 763.6202% | |
| -46.9813% | |
| -60.6377% | |
| 37.6968% | |
| -87.0053% | |
| -18.1555% | |
| 178.2863% | |
| -44.526% | |
| -19.9248% | |
| 61.0086% | |
| -59.6718% | |
| -37.6369% | |
| -22.7355% | |
| -35.3304% | |
| 5.9841% | |
| 42.0151% | |
| 11.9673% | |
| 14.8893% | |
| -12.845% | |
| 19.2256% | |
| 33.5413% | |
| -3.9666% | |
| 54.2372% | |
| 47.3016% | |
| 36.8114% | |
| 88.8356% | |
| 112.2591% | |
| 30.6601% | |
| 122.2492% | |
| 155.3015% | |
| 108.184% | |
| 285.4854% | |
| 203.6937% | |
| 61.629% | |
| 52.2795% | |
| 1,171.7172% | |
| 1.805% | |
| 130.1084% | |
| 148.0388% | |
| 97.6458% | |
| 115.9248% | |
| 20.4948% | |
| 11.0286% | |
| -71.0822% | |
| -182.3695% | |
| -125.2602% | |
| 36.8023% | |
| -26.8187% | |
| -8.4872% | |
| 13.8734% | |
| -3.6534% | |
| -42.2488% |